

D1
D1 E1
(a) comprises at least two T-cell epitope peptides derived from cedar pollen allergen Cry j 1 and at least two T-cell epitope peptides derived from cedar pollen allergen Cry j 2;

(b) is capable of inducing proliferation of T-cell clones specific to each of said T-cell epitope peptides; and

(c) is capable of dose-dependently inducing proliferation of peripheral lymphocytes from a cedar pollinosis patient.

Claim 4 (Amended):

D2
The peptide-based immunotherapeutic agent of claim 1, further comprising a site that is cleaved *in vivo*.

Claim 5 (Amended):

The peptide-based immunotherapeutic agent of claim 4, wherein said site is an arginine or lysine dimer.

D3

Claim 6 (Amended):

The peptide-based immunotherapeutic agent of claim 1, wherein said polypeptide contains the amino acid sequence of SEQ ID NOS: 1, 2, or 3 or immunostimulatory fragments of SEQ ID NOS: 1, 2, or 3. *Ac*

Claim 13 (Amended):

D4 *Ar*
The peptide-based immunotherapeutic agent according to claim 1, wherein each of said T-cell epitopes consists of minimum core sequences that stimulate T-cell proliferation.

✓ ✓ ✓ ✓ ✓ ✓
Please cancel claims 3, 7-12, 14-16, and 18-30.

Please add the following new claims:

Rule 1.12(e)
~~31~~ 49. The peptide-based immunotherapeutic agent of claim 1, wherein each of said T-cell epitope peptides contains no cysteine residue.

D5
~~32~~ 50. The peptide-based immunotherapeutic agent of claim 1, wherein said polypeptide molecule comprises at least one T-cell epitope peptide restricted by HLA class II DR molecule, at least one T-cell epitope peptide restricted by HLA class II DQ molecule, and at least one T-cell epitope peptide restricted by HLA class II DP molecule.

~~33~~ 51. The peptide-based immunotherapeutic agent of claim ~~50~~ 50, wherein said DR molecule is DRB5*0101, DRB4*0101, DRB1*0901, or DRB1*1501, said DQ molecule is DQA1*0102-DQB1*0602, and said DP molecule is DPA1*0101-DPB1*0501, DPA1*0202-DPB1*0501, or DPA1*0101-DPB1*0201.

~~34~~ 52. The peptide-based immunotherapeutic agent of claim ~~50~~ 50, wherein said polypeptide molecule consists of the amino acid sequence described in SEQ ID NO:1.

~~35~~ 53. A method for treating or preventing the incidence of cedar pollinosis, the method comprising administering an effective amount of a peptide-based immunotherapeutic agent comprising a linear polypeptide molecule, wherein said polypeptide:

(a) comprises at least two T-cell epitope peptides derived from cedar pollen allergen Cry j 1 and at least two T-cell epitope peptides derived from cedar pollen allergen Cry j 2;

(b) is capable of inducing proliferation of T-cell clones specific to each of said T-cell epitope peptides; and

(c) is capable of dose-dependently inducing proliferation of peripheral lymphocytes from a cedar pollinosis patient.

Rule 1.126
36 54. The method of claim *53*, wherein said peptide-based immunotherapeutic agent further comprises a site that is cleaved *in vivo*.

37 55. The method of claim *54*, wherein said site is an arginine or lysine dimer.

38 56. The method of claim *53*, wherein said T-cell epitope peptides contain no cysteine residues.

39 57. The method of claim *53*, wherein said polypeptide contains the amino acid sequence of SEQ ID NOs:1, 2, or 3, or immunostimulatory fragments of SEQ ID NOs:1, 2, or 3.

D5 58. The method of claim *53*, wherein said polypeptide molecule comprises at least one T-cell epitope peptide restricted by HLA class II DR molecule, at least one T-cell epitope peptide restricted by HLA class II DQ molecule, and at least one T-cell epitope peptide restricted by HLA class II DP molecule.

40 59. The method of claim *58*, wherein said DR molecule is DRB5*0101, DRB4*0101, DRB1*0901, or DRB1*1501, said DQ molecule is DQA1*0102-DQB1*0602, and said DP molecule is DPA1*0101-DPB1*0501, DPA1*0202-DPB1*0501, or DPA1*0101-DPB1*0201.

41 60. The method of claim *58*, wherein polypeptide molecule consists of the amino acid sequence described in SEQ ID NO:1.

42 61. The method of claim *53*, wherein each of said T-cell epitope peptides consists of minimum core sequences which stimulate T-cell proliferation.

43 62. The method of claim *61*, wherein said core sequence is SEQ ID NO:7.

44 63. The method of claim *53*, wherein said T-cell epitope peptides are analog peptides in which one or more amino acids of the T-cell epitope peptides are substituted.

Rule 1.126

~~46~~ 64. The method of claim ~~63~~⁴⁵, wherein said analog peptide has the amino acid sequence of SEQ ID NO:14.

D5

~~47~~⁶⁵ The method of claim ~~53~~³⁵, which further comprises a pharmaceutically acceptable carrier or diluent.

~~48~~⁶⁶ The peptide-based immunotherapeutic agent of claim 1, wherein said T-cell epitope peptides are analog peptides in which one or more amino acids of the T-cell epitope peptides are substituted.